TARGETING AND THERAPY OF TUMORS WITH MONOCLONAL ANTIBODY

用单克隆抗体靶向和治疗肿瘤

• 批准号: 3175436
• 负责人: Tsann Ming Chu
• 金额: $ 14.17万
• 依托单位: ROSWELL PARK CANCER INSTITUTE
• 依托单位国家: 美国
• 财政年份: 1984
• 资助国家: 美国
• 起止时间: 1984-08-15 至 1991-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3175436
• 关键词: adenocarcinoma; antibody specificity; athymic mouse; biological response modifiers; breast neoplasms; cancer registry /resource; carcinoma; cell mediated cytotoxicity; combination cancer therapy; doxorubicin; glycoproteins; histopathology; human therapy evaluation; human tissue; mesothelioma; mixed tissue /cell culture; molecular oncology; monoclonal antibody; neoplasm /cancer chemotherapy; neoplasm /cancer immunotherapy; neoplasm /cancer radionuclide diagnosis; ovary neoplasms; radioimmunoassay; radiotracer; tumor antigens; xenotransplantation

Monoclonal antibody F36/22 (IgG3, recognizes a glycoprotein with Mr of 700-1000K) has been shown immunohistochemically to be reactive with all human common epithelial ovarian cancers, while normal ovary expresses no detectable level of immunostain. Human exfoliated ovarian tumor cells are usually disseminating throughout the entire peritoneal cavity, and represent an ideal target for therapeutic manipulation in a confined compartment. A recently available human ovarian carcinoma xenograft in female athymic mice, NIH:OVCAR_3, expresses antigen recognized by monoclonal antibody F36/22 and resembles the human disease by producing ascites and intra-abdominal carcinomatosis. Using monoclonal antibody F36/22 as the probe and NIH:OVCAR-3 as the in vivo model, we will develop and eva;iate effective radioimmunotherapy for the targeting and elimination of peritoneal ovarian tumor seedings. Adriamycin, acommonly used cytotoxic agent in ovarian cancer, will be conjugated to monoclonal antibody F36/22 as the probe and NIH:OVCAR as the in vivo model, we will develop and evaluate effective radioimmunotherapy for the targeting and elimination of peritoneal ovarian tumor seedings. Adriamycin, a commonly used cytotoxic agent in ovarian cancer, will be conjugated to monoclonal antibody F36/22 for intracavity immunochemotherapy of ovarian tumor. Effectiveness of both therapies will be potentiated by biological response modifiers. The proposed approaches to the use of a unique monoclonal antibody in targeting and therapy of ovarian cancer in a confined cavity compartment with little or no communication with toher body compartments will generate defined and useful preclinical information.

单克隆抗体F36/22（IgG 3，识别糖蛋白， 700- 1000 K的Mr）已在化学上被证明是 与所有人类常见的上皮性卵巢癌反应，而 正常卵巢未表达可检测水平的免疫染色。 人类 脱落的卵巢肿瘤细胞通常散布在 整个腹膜腔，并代表了理想的目标， 在封闭的空间里进行治疗操作。 一个最近 在雌性无胸腺小鼠中可获得的人卵巢癌异种移植物， NIH：OVCAR_3，表达单克隆抗体识别的抗原 F36/22，与人类疾病相似，产生腹水， 腹腔内癌病 使用单克隆抗体F36/22 以NIH：OVCAR-3为体内模型， 和伊娃;晚期有效的放射免疫治疗， 腹腔卵巢肿瘤切除。 阿霉素， 卵巢癌常用的细胞毒性药物， 偶联单克隆抗体F36/22作为探针，NIH：OVCAR 作为体内模型，我们将开发和评估有效的 放射免疫治疗的目标和消除腹膜 卵巢恶性肿瘤 阿霉素，一种常用的细胞毒性药物， 卵巢癌中的药物，将与单克隆抗体结合 F36/22在卵巢肿瘤腔内免疫化疗中的应用 两种疗法的有效性将通过生物学 反应调节剂。 建议的使用独特的 单克隆抗体在卵巢癌靶向治疗中的应用 一个封闭的腔室，很少或没有与 到她的身体隔间将产生定义和有用的 临床前信息。